Get Live Data

Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globallyView Video
Firering Strategic Minerals : from explorer to producer
Firering Strategic Minerals: From explorer to producerView Video

Latest Share Chat

  2. Share Prices
  3. Biopharma Cred. Share Price
  4. Biopharma Cred. Share Regulatory News
  5. STATEMENT RE COHERUS BIOSCIENCES, INC.

Pin to quick picksBiopharma Cred. Regulatory News (BPCR)

Biopharma Cred. Information

Share Price Information for Biopharma Cred. (BPCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.85
Bid: 0.84
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.01 (1.19%)
Open: 0.85
High: 0.00
Low: 0.00
Prev. Close: 0.85
BPCR Live PriceLast checked at -
BioPharma Credit is an Investment Trust

To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

STATEMENT RE COHERUS BIOSCIENCES, INC.

10 May 2024 15:11

RNS Number : 0397O
BioPharma Credit PLC
10 May 2024
 

BioPharma Credit PLC

10 May 2024

 

 

 

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

STATEMENT RE Coherus BIOSCIENCES, Inc.

 

Pharmakon Advisors, LP, the investment manager of the Company, notes the announcement released 9 May 2024 by Coherus Biosciences, Inc. ("Coherus") regarding entering into a combined term loan and product royalty financing agreement with Barings (the "New Financing"). The New Financing allowed Coherus to fully pay off its remaining USD$75 million senior secured term loan, of which the Company had an investment of USD$37.5 million.

 

The Company had previously announced on 10 January 2022 an investment in a senior secured loan to Coherus of up to USD$150 million in up to three tranches. The Company had previously funded US$125 million, of which USD$87.5 million was repaid as referenced in the Company's announcement on 6 February 2024. The remaining USD$37.5 million was repaid to the Company in connection with the New Financing. In connection with this final repayment, the Company received US$39.8 million in total, including USD$2.3 million of accrued interest, and prepayment and make-whole fees.

 

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 509

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUBUAUPCGCU
12345678910
Date   Source Headline
15th Feb 20184:30 pmRNSHolding(s) in Company
8th Feb 20187:00 amRNSNew Investment
22nd Jan 20184:00 pmRNSNet Asset Value(s)
2nd Jan 20181:00 pmRNSTotal Voting Rights
27th Dec 20172:30 pmRNSHolding(s) in Company
27th Dec 20177:00 amRNSHolding(s) in Company
14th Dec 20176:30 pmRNSResults of Placing
14th Dec 20177:00 amRNSProposed Placing of Shares
13th Dec 20174:00 pmRNSNet Asset Value(s)
11th Dec 20177:00 amRNSPotential Issue of Shares
8th Dec 20175:00 pmRNSNew Investment
7th Dec 20174:45 pmRNSDividend Declaration
5th Dec 20177:00 amRNSNew Acquisition
21st Nov 20174:00 pmRNSNet Asset Value(s)
21st Nov 20171:50 pmRNSAnnouncement of First Major Investment Since IPO
13th Nov 20174:30 pmRNSHolding(s) in Company
20th Oct 20175:00 pmRNSHolding(s) in Company
20th Oct 20174:00 pmRNSNet Asset Value(s)
21st Sep 201710:03 amRNSNet Asset Value(s)
21st Sep 20177:00 amRNSHalf-year Report
24th Aug 20173:15 pmRNSNotice of Results
22nd Aug 20173:22 pmRNSNotice of Results
21st Aug 20174:00 pmRNSNet Asset Value(s)
21st Jul 20174:00 pmRNSNet Asset Value(s)
30th Jun 20174:30 pmRNSReduction of share premium account
19th Jun 20174:00 pmRNSNet Asset Value(s)
22nd May 20174:00 pmRNSNet Asset Value(s)
3rd May 20172:05 pmRNSCorrection: Final Results of Issue
25th Apr 20174:14 pmRNSNet Asset Value(s)
12th Apr 201711:24 amRNSHolding(s) in Company
6th Apr 20176:00 pmRNSCorrection: Total Voting Rights
6th Apr 20173:45 pmRNSHolding(s) in Company
6th Apr 20173:45 pmRNSHolding(s) in Company
5th Apr 20175:30 pmRNSHolding(s) in Company
5th Apr 20174:30 pmRNSHolding(s) in Company
3rd Apr 20173:00 pmRNSTotal Voting Rights
31st Mar 20176:00 pmRNSHolding(s) in Company
31st Mar 20172:15 pmRNSDirector/PDMR Shareholding
31st Mar 20171:45 pmRNSTotal Voting Rights
30th Mar 20171:00 pmRNSDirector/PDMR Shareholding
29th Mar 201711:00 amRNSHolding(s) in Company
29th Mar 201710:30 amRNSDirector/PDMR Shareholding
28th Mar 201710:30 amRNSDirector/PDMR Shareholding
28th Mar 201710:30 amRNSDirector/PDMR Shareholding
28th Mar 201710:30 amRNSDirector/PDMR Shareholding
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.